peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

gastric peptide fragment

BPC-157

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

An introduction is not yet available. The findings below address specific research questions, not a complete account of this peptide.

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

Researchers fabricated a chitosan/BPC-157 (CH/BPC) composite hydrogel and characterized it.

Sources[2]pubmedFabrication and characterization of biocompatible BPC-157 based chitosan hydrogel.In this study, CH/BPC composite hydrogel was fabricated and characterized for their physicochemical properties.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “In this study, CH/BPC composite hydrogel was fabricated and characterized for their physicochemical properties.”

    Fabrication and characterization of biocompatible BPC-157 based chitosan hydrogel. · Abstract

    pubmed:42555375:cc1872d51472:cc1872d51472

How does it work?

Target, response, and disposition.

Mechanism

In this study, BPC-157 inhibited AChE competitively (it competed with the substrate).

Sources[1]pubmedBPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase.All tested compounds exhibited a competitive mechanism of inhibition, as evidenced by increased Michaelis-Menten constant (Km) values with unchanged maximum velocity (Vmax), indicating competition with the substrate at the catalytic site of AChE.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “All tested compounds exhibited a competitive mechanism of inhibition, as evidenced by increased Michaelis-Menten constant (Km) values with unchanged maximum velocity (Vmax), indicating competition with the substrate at the catalytic site of AChE.”

    BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase. · Abstract

    pubmed:42278509:615285aef10d:615285aef10d

What has been studied?

What the evidence says.

Comparative evidence

This comparison is limited to the in vitro potency metrics reported (Ki and IC50) and does not establish differences in clinical effects.

Sources[1]pubmedBPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase.Among the tested compounds, CIARA-1 demonstrated the highest inhibitory potency, reflected by the lowest inhibition constant (Ki= 0.24 mM) and IC50value (2.52 mM), followed by CIARA-2 (Ki= 0.29 mM; IC50= 2.73 mM) and BPC-157 (Ki= 0.48 mM; IC50= 2.80 mM).
Reported result
BPC-157 Ki= 0.48 mM; IC50= 2.80 mM vs CIARA-1 Ki= 0.24 mM; IC50 2.52 mM; CIARA-2 Ki= 0.29 mM; IC50 2.73 mM
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Among the tested compounds, CIARA-1 demonstrated the highest inhibitory potency, reflected by the lowest inhibition constant (Ki= 0.24 mM) and IC50value (2.52 mM), followed by CIARA-2 (Ki= 0.29 mM; IC50= 2.73 mM) and BPC-157 (Ki= 0.48 mM; IC50= 2.80 mM).”

    BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase. · Abstract

    pubmed:42278509:615285aef10d:615285aef10d

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, effect, interaction, regulatory, safety
  • 122 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (83), assurance_score_below_0.72 (35), current_regulatory_source_required (24), extraction_ambiguity (108), high_risk_requires_regulatory_or_two_independent_sources (38), no_direct_support (117), proposal_not_staged (5)
  • A source-backed introductory overview is not yet available.

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase. ↗

    pubmed · published 2026-05-30 · retrieved 2026-08-25T22:58:23Z

  2. Fabrication and characterization of biocompatible BPC-157 based chitosan hydrogel. ↗

    pubmed · published 2026-08-01 · retrieved 2026-08-25T22:58:23Z

Publication history and provenance

Version 8 · Automated assessment · 2026-08-26T08:42:26Z

ab16a732d082b1e2c232295cacfe39d03c0936f1bf8a34cef9f2057e2dd331cb